Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Saudi Pharmaceutical Industries & Medical Appliances ROCE % Related Terms
Saudi Pharmaceutical Industries & Medical Appliances ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saudi Pharmaceutical Industries & Medical Appliances ROCE % Chart
Saudi Pharmaceutical Industries & Medical Appliances Annual Data
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) has a ROCE % of 15.73% as of Mar. 2026.
Is Saudi Pharmaceutical Industries & Medical Appliances' ROCE % too high?
Saudi Pharmaceutical Industries & Medical Appliances' current ROCE % is 15.73%. The Drug Manufacturers industry median ROCE % is 7.01. Saudi Pharmaceutical Industries & Medical Appliances' value of 15.73% is 124.4% above this industry median. Overall, Saudi Pharmaceutical Industries & Medical Appliances has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Saudi Pharmaceutical Industries & Medical Appliances' ROCE % compare to ZTS and UTHR?
Saudi Pharmaceutical Industries & Medical Appliances' ROCE % of 15.73% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Saudi Pharmaceutical Industries & Medical Appliances' value of 15.73% is 124.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saudi Pharmaceutical Industries & Medical Appliances's current ROCE % of 15.73% is 124.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saudi Pharmaceutical Industries & Medical Appliances's current ROCE % is 15.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saudi Pharmaceutical Industries & Medical Appliances stock overvalued right now?
Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) is currently considered Fairly Valued. The stock's GF Value™ is ﷼31.13, compared to a current price of ﷼28.26 — trading 9.2% below its estimated fair value. The current ROCE % is 15.73% and 124.4% above the Drug Manufacturers industry median of 7.01. Saudi Pharmaceutical Industries & Medical Appliances' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070), the current ROCE % is 15.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) Overvalued in 2026?
Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances stock appears to be undervalued.
The current stock price of ﷼28.26 is trading 9.2% below its estimated GF Value™ of ﷼31.13.
GuruFocus considers Saudi Pharmaceutical Industries & Medical Appliances to be Fairly Valued.
Key valuation signals for SAU:2070:
ROCE %: 15.73%
GF Value™: ﷼31.13 vs. price of ﷼28.26 (9.2% below fair value)
Industry Position: 124.4% above the Drug Manufacturers median
No single metric tells the full story. See the SAU:2070 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saudi Pharmaceutical Industries & Medical Appliances Business Description
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. The segments of the company are Pharmaceutical Manufacturing, Trading and Distribution services, and Healthcare Services, out of which the company derives maximum revenue from the Pharmaceutical Manufacturing segment. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco, and Algeria.
69GF Score
Get the complete analysis for SAU:2070
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:2070 has been successfully added to your 
